Taylor SA, et al. - In the prospective Streamline C trial with 1020 subjects, investigators prospectively compared the diagnostic accuracy and effectiveness of whole-body MRI (WB-MRI)-based staging pathways with standard pathways in colorectal cancer. Patients eligible with newly diagnosed colorectal cancer were 18 years of age or older. Pathway sensitivity was 67% for WB-MRI and 63% for standard pathways and agreement with the multidisciplinary team's final treatment decision was 96% for WB-MRI and 95% for the standard pathway. Findings indicated that WB-MRI staging pathways have similar accuracy to standard pathways and decrease the number of tests, staging time and cost required. Data reported that the mean staging costs per-patient were £216 for WB-MRI and £285 for standard pathways. No adverse image-related events have been reported.